San Jose's Ariosa Diagnostics, Inc. Takes Pre-Natal Genetic Test To Wall Street, Eyes $69 Million IPO

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

San Jose, CA-based startup Ariosa Diagnostics has grown to become one of the key players in an emerging industry battle to market pre-natal genetic tests, where parents can figure out whether the child they’re about to have is likely to have a chromosomal abnormality such as Down Syndrome. Now, however, it’s about to seek Wall Street’s help to finance the effort. Ariosa plans to raise up to $69 million through an IPO and trade on the Nasdaq under the ticker symbol “AROS.” JP Morgan Securities, Leerink Partners, Citigroup Global Markets, and William Blair & Co. are underwriting the IPO, which Ariosa wants to pull off largely to ramp up its sales force and help market its diagnostic test, known as “Harmony.”

Help employers find you! Check out all the jobs and post your resume.

Back to news